Brain-Computer Interface Companies: Why Forced Growth Backfires

Sofía García · 2026-09-15

The brain-computer interface (BCI) industry is buzzing with excitement. Companies are racing to develop technology that connects human brains directly to computers, promising to revolutionize everything from medicine to gaming. But according to a recent report from 36Kr, many BCI companies are pursuing forced, premature growth that ultimately proves counterproductive. Let's dig into why this happens and what it means for the future of this fascinating field. ### The Allure of Brain-Computer Interfaces BCIs sound like something out of science fiction. Imagine controlling a computer with your thoughts or restoring movement to paralyzed limbs. The potential is enormous. Companies like Neuralink, Kernel, and Emotiv are working on different approaches, from invasive implants to non-invasive headsets. Investors are pouring money into the sector, hoping to catch the next big thing. But here's the catch: the technology is still in its infancy. We're decades away from widespread consumer adoption. Yet many startups are acting as if we're on the verge of a breakthrough, pushing products to market before they're ready. ### The Problem with Premature Scaling When companies prioritize growth over substance, they run into trouble. They might release half-baked products that don't work well, damaging public trust. Or they might overpromise and underdeliver, leading to disappointed customers and skeptical investors. In the BCI field, where safety and efficacy are paramount, this can be especially harmful. One common mistake is focusing on flashy demos rather than rigorous science. A company might show a monkey playing a video game with its mind, but that doesn't mean the technology is ready for humans. Another issue is burning through cash too quickly. Startups raise large rounds and hire aggressively, only to realize they can't meet milestones. When the money runs out, they either shut down or get acquired for pennies on the dollar. ### Why Forced Growth Happens So why do companies fall into this trap? Several reasons: - **Investor pressure:** Venture capitalists expect rapid returns. They push startups to scale quickly, even if the technology isn't ready. - **Competitive frenzy:** When rivals announce breakthroughs (or just hype), others feel compelled to keep up. - **Media hype:** Sensational headlines create unrealistic expectations, and companies try to live up to them. - **Founder ego:** Some entrepreneurs believe they can defy the odds and succeed where others failed. But as the 36Kr article points out, this approach often backfires. Instead of building a sustainable business, companies end up in a vicious cycle of raising money, missing targets, and eventually collapsing. ### The Counterproductive Cycle Let's walk through how it typically unfolds. A BCI startup raises a seed round based on a bold vision. They hire a team, set up a lab, and start developing prototypes. Early results are promising, so they raise a Series A. Now they need to show progress, so they rush to announce a product. But the product is buggy or limited. Customers complain. The company pivots, raising more money to fix the issues. Meanwhile, competitors are catching up. The pressure mounts. Eventually, the company either gets acquired for a low price or shuts down. This pattern isn't unique to BCIs; it happens in many deep-tech fields. But BCIs are particularly vulnerable because the science is so complex and the regulatory hurdles are high. You can't just ship a software update; you need clinical trials and FDA approvals. ### What Should Companies Do Instead? Instead of forced growth, BCI companies should focus on sustainable progress. That means: - **Investing in long-term research:** Don't rush to market. Build a solid scientific foundation. - **Setting realistic milestones:** Underpromise and overdeliver. - **Educating the public:** Help people understand what's possible and what's not. - **Collaborating with regulators:** Engage with the FDA early to navigate the approval process. - **Focusing on niche applications:** Start with medical use cases where the need is clear and the regulatory path is defined. As the old saying goes, "Rome wasn't built in a day." The same applies to brain-computer interfaces. Patience and persistence will pay off more than rushed growth. ### The Road Ahead The BCI field is still exciting, and the potential is real. But companies need to avoid the trap of premature scaling. By taking a measured approach, they can build lasting businesses that truly improve lives. Investors, too, should temper their expectations and support companies that prioritize science over hype. In the end, the winners in this space won't be the fastest movers but the smartest ones. They'll be the companies that understand the technology's limits and work steadily to overcome them. So, if you're following the BCI industry, keep an eye out for those who are playing the long game. They're the ones who will ultimately succeed.